Bolt Biotherapeutics, Inc.

Equities

BOLT

US0977021049

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 18/06/2024 am IST 5-day change 1st Jan Change
0.7538 USD -0.82% Intraday chart for Bolt Biotherapeutics, Inc. +0.51% -32.70%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bolt Biotherapeutics, Inc. Announces Management Changes CI
Bolt Biotherapeutics, Inc. Announces Chief Executive Officer Changes CI
Top Midday Decliners MT
Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% MT
Top Premarket Decliners MT
Investors Await Key Inflation Data for April as US Futures Remain Flat in Wednesday's Premarket MT
Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform From Outperform, Adjusts PT to $1 From $3 MT
Guggenheim Downgrades Bolt Biotherapeutics to Neutral From Buy MT
HC Wainwright Downgrades Bolt Biotherapeutics to Neutral From Buy MT
Stifel Downgrades Bolt Biotherapeutics to Hold From Buy, Adjusts Price Target to $1.50 From $6 MT
Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating Bdc-1001 in Patients with Her2-Positive Breast Cancer Previously Treated with Enhertu CI
Bolt Biotherapeutics Insider Sold Shares Worth $128,993, According to a Recent SEC Filing MT
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Bolt Biotherapeutics, Inc. Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress CI
Bolt Biotherapeutics Begins Dosing in Advanced Cancers Phase 1/2 Study of BDC-3042 MT
Sector Update: Health Care Stocks Rising in Late Afternoon Trading MT
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
Bolt Biotherapeutics Says US FDA Granted Orphan Drug Designation for BDC-1001 for Gastric Cancer MT
Bolt Biotherapeutics Says Candidate Cancer Treatment Secures Patent MT
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
North American Morning Briefing : Hopes Build for -3- DJ
SVB Securities Upgrades Bolt Biotherapeutics to Outperform From Market Perform, Price Target is $4 MT
Chart Bolt Biotherapeutics, Inc.
More charts
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Trastuzumab imbotolimod is in Phase 2 clinical. BDC-3042, an agonist antibody targeting Dectin-2, is in a Phase 1 dose-escalation trial. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. It developed a lead agonist antibody that binds to Dectin-2 and activates human tumor-associated macrophages. It is developing multiple Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
0.76 USD
Average target price
1.25 USD
Spread / Average Target
+64.47%
Consensus
  1. Stock Market
  2. Equities
  3. BOLT Stock
  4. News Bolt Biotherapeutics, Inc.
  5. Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50%